New studies show death rates significantly lower when major risk factors for cardiovascular disease and coronary heart disease are absent

November 30, 1999

Data from two long-term studies show that people with the most favorable levels of all three major coronary risk factors (blood cholesterol, blood pressure, and cigarette use) experienced markedly lower death rates from heart attack and stroke, as well as notably increased life spans.

A report on the two studies, the Multiple Risk Factor Intervention Trial (MRFIT), and the Chicago Heart Association Detection Project in Industry (CHA), appears in the December 1, 1999 issue of the Journal of the American Medical Association.

"A nearly 80 percent lower rate of coronary heart disease deaths among low-risk middle aged adults compared with those of average risk is an astounding difference in the rates of heart and cardiovascular disease" said Dr. Claude Lenfant, Director of the National Heart, Lung, and Blood Institute (NHLBI). "Unfortunately, only a small percent of adults is at low risk. Our challenge for the 21st century is to prevent risk factors from developing in the first place by encouraging healthy behaviors early in life," added Dr. Lenfant.

MRFIT, a 16-year study funded by the NHLBI, a component of the National Institutes of Health, looked at two groups of men (ages 35-39 and ages 40-57) in 18 cities. CHA also studied two groups of men (ages 18-39 and ages 40-59), as well as one group of women (ages 40-59) in 84 Chicago companies and other organizations over a period of 22 years. CHA was co-funded by the American Heart Association and NHLBI.

Of the 366,559 people who participated in the two studies, just 5 - 10 percent in all groups were considered low risk for cardiovascular disease and coronary heart disease. Criteria for low risk in both studies included blood cholesterol level (<200mg> For both African Americans and whites, and irrespective of socioeconomic status, the findings show that the death rate from coronary heart disease (CHD) was much lower for low-risk groups than for other study participants; by 86 percent to 92 percent for low-risk young adult men (i.e., men ages 18-39), and by 77 percent to 79 percent for low-risk middle-aged adults (i.e., men and women ages 40-59). For low-risk adult men, deaths from CHD accounted for only 6 percent to 8 percent of all deaths versus 25 percent to 29 percent for other participants in the study.

There were no deaths from stroke in the two young adult low-risk groups. For the low-risk middle-aged groups, the age-adjusted death from stroke was lower by 52 percent to 76 percent compared to others. Death from all causes was consistently, markedly, significantly lower for low-risk versus others - by 50 percent to 58 percent for men and 40 percent for women. The estimated greater life expectancy for low-risk versus others ranged from 5.8 years to 9.5 years.
-end-
To arrange an interview with Dr. Jeremiah Stamler, the lead author of the report, please call Northwestern University Medical School, 312-503-8928.

For more information about cardiovascular disease and heart health, visit the NHLBI Web site at www.nhlbi.nih.gov.

NIH/National Heart, Lung and Blood Institute

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.